Skip to main content
LSL Pharma Group Inc. logo

LSL Pharma Group Inc. — Investor Relations & Filings

Ticker · LSL ISIN · CA50190N1042 TSXV Manufacturing
Open in API
Filings indexed 304 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country CA Canada
Listing TSXV LSL

About LSL Pharma Group Inc.

https://www.groupelslpharma.com/en

LSL Pharma Group Inc. is an integrated pharmaceutical company focused on the development, manufacturing, and commercialization of specialized life sciences products. The company operates multiple manufacturing facilities dedicated to producing a diverse portfolio, including sterile pharmaceutical products, natural health products (NHPs), cosmetic products, food supplements, and vitamins, often in tablet and capsule formats. LSL Pharma Group functions as a Contract Development and Manufacturing Organization (CDMO) for natural and pharmaceutical segments. The company leverages its integrated capabilities to serve domestic and international markets, including strategic distribution agreements aimed at supplying high-quality pharmaceuticals to alleviate drug shortages in hospital environments.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 90% confidence The document is a Form 52-109 FV2 'Certification of Interim Filings' by the CEO of a venture issuer, providing attestations on the interim financial report and MD&A without containing any actual financial data. It is an officer’s certification letter rather than the interim report itself. Under the CERTIFICATION RULE, such attestations are classified as Regulatory Filings (RNS).
2026-05-22 English
Interim financial statements/report – English.pdf
Management Reports Classification · 95% confidence The document is clearly a standalone Management’s Discussion and Analysis (MD&A) for the first quarter ended March 31, 2026. It provides narrative commentary on financial performance, non-IFRS measures, segment reporting, and forward-looking statements, without presenting the full financial statements themselves. This matches the definition of Management Reports (MDA).
2026-05-22 English
Interim MD&A - English.pdf
Management Reports Classification · 92% confidence The document is a standalone Management’s Discussion & Analysis (MD&A) for the quarter ended March 31, 2026, providing narrative commentary on financial condition, non-IFRS measures, segment performance, and corporate strategy. It does not include the full set of interim financial statements, matching the definition of a Management Report (MDA).
2026-05-22 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 95% confidence The document consists of unaudited condensed interim consolidated financial statements for the three-month periods ended March 31, 2026 and 2025, prepared under IFRS in accordance with IAS 34 “Interim Financial Reporting.” It includes comprehensive balance sheets, income statements, cash flow statements, statement of changes in equity, and accompanying notes. This is a full interim/quarterly financial report (not just an announcement or summary), so it should be classified as an Interim / Quarterly Report. Q1 2026
2026-05-22 English
News release - English.pdf
Regulatory Filings
2026-04-30 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings
2026-04-29 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.